Compare Automatic Data Processing Inc (ADP) vs Amgen, Inc. (AMGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Automatic Data Processing Inc vs Amgen, Inc. — how do they compare? Automatic Data Processing Inc trades at $269.97 (market cap $107.69B), while Amgen, Inc. trades at $412.15 (market cap $224.14B). The key difference: Amgen, Inc. is far larger — about 2.1× Automatic Data Processing Inc's market cap, and Automatic Data Processing Inc pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| ADP | AMGN | |
|---|---|---|
Market Cap | $107.69B | $224.14B |
Sector | Industrials | Health |
52-Week High | $309.03 | $417.20 |
52-Week Low | $188.79 | $271.18 |
Enterprise Value | $108.73B | $267.45B |
Dividend Yield | 2.51% | 2.43% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Automatic Data Processing Inc
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
